Reprocell and Medicines Discovery Catapult partner to speed drug development

Cells
The European branch of Japan’s Reprocell, which supports stem cell research and preclinical drug trials, is partnering with Medicines Discovery Catapult to focus on accelerating drug development for U.K. biotech firms. (Pixabay)

The European branch of Japan’s Reprocell, which supports stem cell research and preclinical drug trials, is partnering with Medicines Discovery Catapult to focus on accelerating drug development for U.K. biotech firms.

As part of the deal, Reprocell will provide live human tissue that will be used to predict how drugs will behave in patients and whether those compounds have a good chance of success in clinical trials. Reprocell will have access to Medicines Discovery’s virtual research and development platforms.

Financial terms of the partnership weren’t disclosed.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Ethically sourced human tissue samples are such an important resource for the prediction of efficacy and safety of novel drug compounds and are becoming increasingly important in the area of precision medicine,” Dr. Karen Bingham, Reprocell’s COO, said in a statement. “It’s crucial that the (National Health Service), industry and academia work together through collaborations such as Medicines Discovery Catapult in order to maximize use of this precious resource.”

Last year, Medicines Discovery announced a partnership with the National Centre for the Replacement, Refinement & Reduction of Animals in Research to accelerate in vitro research models for new products as well as reduce the number of animals being used in research. It also partnered with AstraZeneca to develop the use of sound waves in mass spectrometry for drug discovery applications.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.